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Introduction 
Diarrheal disease is responsible for a huge burden on human society. Even with 
improvements in the case management, diarrhea is responsible for 1.5 million deaths 
annually, or 1% of deaths in children under 5 years. Although the majority of these deaths 
occur in the developing world, it is a common reason for medical consultation and hospital 
admission in Western societies and exacts an enormous social toll in terms of loss of 
productivity among affected individuals and their caregivers [1].  
Probiotics, commonly known as “good bacteria” can offer health benefits in a number of 
ways when consumed. The use of probiotic microorganisms for the prevention or therapy 
of gastrointestinal disorders is an obvious measure and perhaps the most usual application 
of probiotics because most health effects attributed to them are related directly or 
indirectly to the gastrointestinal tract [2]. In this review, we summarize the available 
evidence on the use of probiotics for diarrheal diseases in children. 
History 
The health benefits of bacteria consumed in food have been known since ages; records 
dating back to as early as the Persian version of the Old Testament. Noble laureate Elie 
Metchnikoff in 1908 suggested that products of proteolytic bacterial action on protein 
resulted in “intestinal autointoxication”. He presented a hypothesis that consumption of 
yogurt containing Lactobacillus lead to reduced number of toxin-producing bacteria in the 
intestine and thus contributed to the long life of Bulgarian peasants [3]. The concept of 
probiotic is derived from the Greek word meaning “for life” and the term came into 
practice in 1965 [4]. Since then the interest in probiotics has grown many folds and 
currently, the market for probiotics has reached to over 60 billion USD [5].  
Definition and properties of probiotics 
The FAO/ WHO defines probiotic as a “live microorganism which, when administered in 
adequate amounts, confer a health benefit to the host” [6]. Following this, the   -
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ABSTRACT 
Diarrhea remains the second leading cause of death in children below 5 years of age; in 
addition it is also the reason for a considerable morbidity in children of all ages throughout 
the globe. Apart from oral rehydration solution, continued feeding, oral zinc and 
antibiotics for diarrhea of bacterial etiology, there have been no other proven measures 
for diarrheal illnesses in children. Probiotics are non-pathogenic live microorganisms. 
When ingested, probiotics can survive passage through the stomach and small bowel. 
Probiotics are supposed to have preventive as well as curative effects on several types of 
diarrhea of different etiologies. 
Keywords: Gastroenteritis, Saccharomyces, Bifidobacterium, Functional food. 
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International Life Science Institute (ILSI) [7] and the European 
Food and Feed Cultures Association (EFFCA) [8] have given 
similar definitions for probiotic: “a live microbial food 
ingredient that, when consumed in adequate amounts, confers 
health benefits on the consumers”. The properties of an ideal 
probiotic should be [9]: 
 of human origin 
 nonpathogenic 
 contains sufficient number of viable cells 
 unaffected to destruction by technical processing 
 unaffected to destruction by gastric acid and bile 
 adhere to intestinal epithelium 
 able to inhabit the gastrointestinal tract, even if for a 
short time 
 producing antimicrobial substances 
 modulating immune responses 
 influencing human metabolic activities (i.e. 
cholesterol assimilation, vitamin production) and 
 undergone in vivo and in-vitro trials to prove any 
attributed probiotic effect and documented a clinical 
benefit 
Common probiotic strains 
Various organisms (bacteria and fungus) have been identified 
as meeting the diagnostic criteria for probiotics. The common 
ones are presented in (table 1). 
Bifidobacterium spp Lactobacillus 
spp 
Saccharomyces 
spp 
B. bifidum L. acidophilus S. boulardii 
B. breve L. casei 
(rhamnosus) 
 
B. lactis L. fermentum  
B. longum L. gasseri  
B. infantis L. johnsonii  
B. adolescents L. lactis  
B. paracasei   
B. plantarum   
B. reuteri   
Table 1. Common probiotic strains 
The indigenous intestinal flora 
There are an estimated 1014 cells in human body, and out of 
this only 10% are not bacteria. The gastrointestinal tract of 
mammals is a complex, dynamic and diverse ecosystem 
comprising of interactions between aerobic and anaerobic, 
nonpathogenic bacteria. There are 400 separate species in this 
complex yet stable colony. The majority of the gut organisms, 
which represent 40% of the fecal weight, are accounted for by 
luminal flora; nevertheless, the organisms present in the fecal 
matter do not necessarily signify the important host-microbial 
symbiosis of the mucosal bound flora [10]. Within first few days 
after birth, the newborn’s gut is colonized with bacteria. A 
diverse range of bacteria inoculates the gut initially; this 
includes Bifidobacteria, Enterobacteria, Bacteroids, Clostridia, 
and Gram-positive cocci. Later on, there are swift changes in 
the flora depending on the mode of delivery, gestational age, 
and diet (breastfeeding/ formula feeding). Vaginally delivered 
breastfed infants have similar colonization to vaginally born 
formula-fed infants at 48 hours of life, indicating a similar 
“inoculums”. However, by 7 days, only 22% of breastfed infants 
are colonized with B. fragilis, as compared to 61% of those fed 
on formula [11]. Interestingly, there is a minimal role of diet in 
the composition of fecal flora in the older child and adult [12].  
Fungi are present in the stools of up to 65% of individuals, 
Candida being the predominant genus. It appears that 
pathogenic colonization by yeast, under normal circumstances, 
is inhibited by the normal bacterial flora. However, alteration 
or destruction of the fecal flora by antibiotics would lead to 
yeast multiplying in great numbers [13].  
Mechanism of action of probiotics in diarrhea 
Although animal and molecular studies have generated a great 
deal of data, most theories remain speculative and 
confirmation of findings in vivo and in human clinical trials have 
been lacking. Almost certainly multiple mechanisms operate 
together and it is clear that single strains may act using 
different mechanisms in different disease processes [14].  
Luminal: Many probiotic organisms elaborate ‘bacteriocins’, 
restricting the growth or pathogenicity of non-homologous 
strains. Other probiotic activities including the production of 
lactic acid, short chain fatty acids and hydrogen peroxide lower 
intraluminal pH and contribute to a hostile environment for 
other potentially pathogenic species. Some probiotic products, 
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such as proteases produced by Saccharomyces boulardii have 
been shown to degrade toxins produced by pathogens such as 
Clostridium deficile, Vibrio cholera or pathogenic Escherichia 
coli [15]. Additionally, probiotics metabolic activity may have 
useful nutritional or clinical activity. It has long been 
appreciated that the enzyme ß-galactosidase produced by 
lactobacilli may be useful in preventing diarrhea in individuals 
with acquired deficiency of this enzyme [16].  
Mucosal: Some probiotic agents are able to bind directly to 
invasive species or to otherwise disrupt their ability to interact 
with or bind to endothelial receptors. Probiotics including 
several species of Lactobacillus have been shown to upregulate 
goblet cell production of mucins and protective ‘trefoil factors’. 
They also stimulate crypt located Paneth cells in the production 
of ‘defensins’, cationic proteins which are able to insert 
themselves into microbial membranes to form destructive 
pores. In addition, probiotics may also influence proteins 
controlling tight junctions between enterocytes, reducing the 
potential for the absorption of harmful macromolecules and 
the ability of luminal pathogens to translocate into the 
submucosal space [17].  
Submucosal: Critical to the development of innate immunity is 
the system for recognizing microbe-associated molecular 
patterns (MAMPs)-conserved regions comprising motifs or 
repeating units from a wide range of molecules including 
lipopolysaccharides, peptidoglycans, and nucleic acids found 
more frequently on the surface of microbial species than on 
host cells. These pattern recognition receptors (PRRs) including 
the toll-like receptors (TLR) on the surface of host cells 
(including dendritic cells in the gut) are key determinants of 
detection and host interaction directing subsequent effector 
response [18]. Adaptive immune responses have also been 
shown to be influenced by the presence of probiotic organisms, 
some of which are able to stimulate immunoglobulin 
(particularly secretory IgA) production and to modulate the 
development and activity of regulatory T-lymphocytes. 
Similarly, probiotics are known to influence the pattern of 
cytokine release as well.  
It is likely that host-microbe signaling takes place continuously 
rather than awaiting recruitment at the time of disease. The 
potential for probiotics to influence this series of interactions 
through the activation of NF-ĸß, thereby controlling DNA 
transcription, the inflammatory response and the balance of 
TH1/TH2 activation, hold exciting promise for the ability of 
these agents to influence chronic inflammatory processes [19]. 
Such effects are also likely to be important in modulating the 
immune response to acute infection within the gastrointestinal 
tract.  
The molecular interactions between host and microbiota have 
been shown to have an influence on the enteric nervous and 
endocrine systems. Experimental work has identified the 
activity of certain probiotic species in inducing opioid and 
cannabinoid receptors in the gastrointestinal tract as well [20].  
Probiotics for diarrhea of viral origin 
Viral agents are responsible for acute diarrheal episodes in 
children throughout the world with Rotavirus being the most 
important agent. A Cochrane database of systematic review 
compiled pooled estimates of benefit for Lactobacillus in acute 
rotavirus diarrhea [Allen SJ 21] and found a reduction in the 
duration of diarrhea of 29 hours (95% CI 16-42 hours), a 
reduction in stool frequency on day 2 following the 
intervention of 1.25 stools per day (95% CI 0.4-2.1). Grandy et 
al [22] studied S. boulardii alone or in combination with three 
other probiotics including two strains of Lactobacillus in 
rotavirus diarrhea. Both products seemed to be associated with 
a reduction in the duration of diarrhea. However, a Turkish 
study found benefit in terms of reduced duration of diarrhea 
for one of only four intervention groups given S. boulardii [23].  
Although a number of treatment studies have reported the 
detection of other (i.e. non-rotavirus) viral agents [24, 25], 
individual isolates have been few in number and no studies 
have reported primary or secondary outcomes for probiotics 
administered for acute diarrheal episodes attributable to 
specific viral etiologies other than rotavirus.  
Similarly, studies of prevention of diarrheal disease have 
generally failed to provide evidence of protection against 
specific viral agents. A Peruvian study in the prevention of 
diarrhea in children aged 6-29 months reported a reduction in 
the detection of adenovirus from stool specimens in a cohort 
supplemented with Lactobacillus GG [26]. But, on the other 
hand, Sur et al. have found no difference in recovery rates for 
adenovirus, rotavirus, norovirus, or astrovirus for children from 
a deprived urban setting of India, receiving L. casei Shirota 
compared with a control cohort [27]. 
Children with HIV (Human immunodeficiency virus) infection 
comprise a special population which is susceptible to diarrheal 
illnesses due to a host of infections. The published studies on 
the efficacy of probiotics in the treatment of diarrhea in this 
population have come to disparate conclusions; some [28, 29] 
but not others [30, 31], finding efficacy. In a large study of 
Malawian children with severe acute malnutrition [32], over 
40% of whom were HIV positive, were randomized to receive a 
multicomponent probiotic containing lactobacilli or placebo. 
The study did not find an improvement in rates of diarrhea for 
probiotic recipients.  
Probiotics for bacterial diarrhea 
Two studies of Lactobacillus rhamnosus GG found no evidence 
of protection for the 15-20% of children with ‘invasive’ 
pathogens, principally Salmonella or Shigella [33]. In the only 
study specifically addressing bacterial disease, there was an 
earlier resolution of diarrhea for LGG (co-treated with 
trimethoprim-sulfamethoxazole) during an outbreak of Shigella 
dysentery in Estonia [34]. Hwe et al [35] described an 
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improvement in stool consistency for 20 children with 
pathogenic E. coli cultured from the stool. However, a three-
species probiotic mixture including Escherichia faecium was not 
found to significantly reduce the duration of diarrhea due to 
Salmonella or Campylobacter in Taiwan [25]. Several studies 
using combination probiotic products (S. boulardii or E. coli 
Nissle 1917) in middle-income countries report overall efficacy 
for groups with significant (10-20%) contributions from 
pathogenic species but sufficient data is not provided to assess 
efficacy by diarrheal pathogen [36, 37, 38, 39].  
A large community prevention study from India [27] 
documented a reduction of diarrheal disease with Aeromonas 
and Cryptosporidium species in Lactobacillus casei Shirota 
recipients; though other bacteria (including pathogenic E. coli), 
viral and protozoal species were recovered at equivalent rates. 
Another study from urban India reported protection against 
dysentery (defined by a parental history of bloody diarrhea), 
although no impact was seen on the overall incidence of 
diarrhea [40].  
Probiotics for parasitic diarrhea 
A Cuban study in children with persistent diarrhea (35 out of 40 
having giardial cysts in stool) improved with administration of 
S. boulardii [41]. In cases of amoebic dysentery, reduced 
duration of bloody diarrhea and a lower rate of cyst excretion 
on day 5 are reported in 25 Turkish children receiving 
Saccharomyces [41]. A randomized trial in 48 symptomatic 
children with Blastocystis hominis demonstrated higher rates 
of clinical cure and disappearance of cysts from the stool with 
probiotics [43].  
Probiotics for Clostridium defficile associated 
diarrhea (CDAD) 
Although a meta-analysis performed by McFarland for the 
treatment of CDAD found evidence in favor of treatment with 
S. boulardii [44], the Cochrane group and other reviewers [45, 
46, 47] have conclude that despite holding promise, currently 
data are not sufficient to make a recommendation for the use 
of Saccharomyces or other Probiotics for the treatment of 
primary or relapsing CDAD.  
Five published studies of the use of Saccharomyces in the 
prevention of antibiotic-associated diarrhea (AAD) have 
provided secondary outcome measures for CDAD. Reviewers 
[45, 48, 49] have concluded that inadequate evidence currently 
exists in order to make a recommendation concerning the role 
of S. boulardii or other Probiotics in the primary prevention of 
CDAD.  
Probiotics for antibiotic associated diarrhea (AAD) 
There have been no published RCT investigating the effect of 
Probiotics for the treatment of non-Clostridium defficile AAD in 
children; thus, their use cannot be recommended at this time.  
A Cochrane meta-analysis of probiotic use of children to 
prevent or ameliorate (i.e. shorten duration and/ or severity) 
AAD [50] documents that probiotics produced a statistically 
significant reduction in the incidence of AAD (RR 0.52; 95% CI 
0.38-0.72) with the number needed to prevent one case of AAD 
being 7. Analysis of secondary outcomes revealed that 
probiotics decreased the mean duration of diarrhea by three-
quarters of a day. The difference in mean stool frequency was 
not statistically significant. Analysis by probiotic strain revealed 
a significant effect for LG and Lactobacillus sporogenes but not 
for boulardii.  
Probiotics for traveler’s diarrhea 
Several studies using lactobacilli have suggested benefit in 
protecting travelers from diarrhea, but in only one study using 
a mixture of strains (containing Lactobacillus acidophilus, 
Lactobacillus bulgaricus, Bifidobacterum bifidum and 
Streptococcus thermophilus) was the reduction in the overall 
incidence of diarrhea statistically significant [51]. Travelers to a 
variety of destinations including North Africa, South America, 
India and Turkey derived some measure of protection from S. 
boulardii [52]. Several attempts have been made to conduct 
meta-analysis from these data, estimating risk ratios marginally 
in favor of probiotics (RR estimates between 0.85 and 0.93) but 
with confidence intervals close to or encompassing the point of 
equivalence [53, 54, 55]. 
Probiotics for diarrhea in children attending day 
care centers 
One RCT documented that a daily administration of L. reuteri 
for 3 months in 336 otherwise healthy, Mexican children 
attending day care centers a significant reduction in the 
number of episodes of diarrhoea, episodes of diarrhoea per 
child, mean duration of diarrhoea episodes and days with 
diarrhea per child both during the intervention and for the next 
3-month follow-up period compared to the placebo group [56]. 
Another RCT carried out in malnourished Indonesian children 
found that the consumption of regular calcium milk with L. 
reuteri compared with regular calcium milk alone reduced the 
risk of diarrhoeal disease [57]. A double-blind RCT from Croatia 
in 210 children attending daycare centers found that that B. 
animalis subsp. lactis BB-12 given for months had no effect on 
the prevention of gastrointestinal [58]. 
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Probiotics for persistent diarrhea 
A Cochrane review of probiotics for persistent diarrhea [59] 
yielded a pooled estimate for reduction in the mean duration 
of diarrhea from 9 to 4 days, with significantly fewer stools on 
day 5 (a reduction from a mean of 5 to fewer than 2 stools per 
day). 
Probiotics for acute diarrhea of undetermined 
etiology 
A 2010 Cochrane database of systematic review provides a 
meta-analysis of 63 studies of probiotic agents involving more 
than 8000 participants, mostly children, conducted in a variety 
of geographical and social settings [21]. Overall conclusions 
suggest that probiotics shorten the duration of diarrhea by 24 
hours {95% confidence interval (CI) 16-33 hours} and for a mean 
difference in stool frequency on day 2 of 0.8 (95% CI 0.4-1.1), 
with a relative risk of continuing diarrhea on day 4 of 0.4 (95% 
CI 0.3-0.5). No adverse effects were attributed in these studies 
to the administration of the probiotic.  
There is still clearly much to learn about how best to use 
probiotics in acute diarrheal disease. Only a few studies have 
directly compared probiotic products [60-63] or ranged doses 
[64, 65]. The Cochrane review [21] found similar pooled 
estimates of efficacy for studies conducted in countries 
categorized by high or low mortality, nevertheless, a 
preponderance of negative studies [66, 67, 68, 69, 70, 71] have 
been reported from resource-limited settings where infectious 
agents and the intestinal microbiota might be expected to be 
different from those of Western societies. Other little-explored 
influences on treatment include the role of prebiotic nutritional 
supplements, breastfeeding [26] or other dietary practices, the 
effects of accompanying or recent antibiotic treatment, the 
availability of clean water and adequate sanitation and other 
currently ill-defined influences on the resident microbiota.  
Uncertainties aside, majority of reviewers and expert 
committees [65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76], 
including American Academy of Pediatrics [77] and European 
Society of Pediatric Gastroenterology Hepatology and Nutrition 
(ESPGHAN) [78] have concluded that preparations containing 
probiotics (of the specific strains studied in these trials) both 
shorten the duration and reduce the severity of acute diarrhea 
in children.  
Safety of probiotics 
Probiotics are considered ‘generally recognized as safe’ (GRAS) 
and well tolerated in humans but case reports have described 
bacteremia and fungemia secondary to probiotics. For 
example, there is a report of a 1-year-old immunocompetent 
child developing fungemia after receiving S. boulardii for 
gastroenteritis [79]. The Mayo Clinic reported eight 
immunocompromised patients post-liver transplant having 
positive blood culture for Lactobacillus [80]. Furthermore, two 
infants with short bowel syndrome were found to be 
bacteremic withprobiotic strains of Lactobacillus GG [81]. Long-
term use of probiotics under antibiotic selection pressure could 
cause antibiotic resistance, and the resistance gene could be 
transferred to other bacteria [82]. The committee on Nutrition 
of the European Society of Pediatric Gastroenterology, 
Hepatology and Nutrition concluded that more studies are 
required to establish the safety and efficacy of probiotics in 
children. Till date safety of probiotics is established in healthy 
infants and children. Caution should be exercised when using 
these in immunocompromised patients or those with 
indwelling central venous catheters. It is out of the purview of 
The American Food and Drug Administration to establish a 
formal regulatory category for functional foods that includes 
probiotics. Variations in products do exist and some studies 
have even found that certain preparations contain no viable 
bacteria.  
Conclusion 
A low-cost probiotic intervention capable of reducing the risks 
of diarrhea in the early years of life, even with modest efficacy, 
would have an enormous impact on the developing world. 
Assuming that efficacy is confirmed for prevention and 
treatment of childhood diarrhea in these settings, a great deal 
of work will be needed for its broad implementation.  
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